Hepatitis B surface antigen quantification as a current-day paradox: Obtaining the gold in the face of diminishing returns

Hepatology

Volumn 49, Issue 4, 2009, Pages 1063-1065

  Perrillo, Robert P ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; VIRUS DNA; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ANTIGEN DETECTION; ANTIVIRAL THERAPY; COMBINATION CHEMOTHERAPY; EDITORIAL; GENOTYPE; GOLD STANDARD; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOASSAY; MONOTHERAPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; IMMUNOLOGY; NOTE;

ANTIVIRAL AGENTS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS;

EID: 65449130738     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22932     Document Type: Editorial

References (18)

1. Hadziyannis SJ, Sevastianos V, Rapti IN, Tassopoulos N. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B [Abstract]. HEPATOLOGY2006;44(Suppl):23A.
2. Lok ASF, McMahon BJ. Chronic hepatitis B. AASLD Practice Guidelines. HEPATOLOGY2007;45:507-539.
3. Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, et al. Delayed clearance of HBsAg in compensated cirrhosis B: Relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998; 93:896-900.
4. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-1758.
5. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-186.
6. Realdi G, Fattovich G, Hadziyannis S, Schalm S, Almasio P, Sanchez-Tapiaas J, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: A multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994;21:656-666.
7. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long-term follow up. HEPATOLOGY2007;45:1187-1192.
8. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. HEPATOLOGY2009; doi:10.1002/hep.22956.
9. Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
10. Buster EHCJ, Flink HJ, Cakaglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long term follow-up of HBeAg-positive patients treated with peginterferon beta-2b. Gastroenterology 2008; 135:459-467.
11. Marcellin P, Piratvisuth T, Brunetto M, Bonino F, Lau GKK, Farci P, et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40-kD) with or without lamivudine: Results of 4 year-follow up [Abstract]. J Hepatol 2008;48:S46.
12. Manensis EK, Hadziyannnis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: A clue from serum HBsAg levels. Antivir Ther 2007;12:73-82.
13. Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended treatment duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 2007;102:2718-2723.
14. Moucari R, Mackiewicz V, Lada O, Ripault M-P, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. HEPATOLOGY2009; doi:10.1002/hep.22744.
15. Brunetto MR, Moriconi F, Bonino F, Lau GKK, Farci P, Yurdaydin C, Piratvisuth T, et al. Hepatitis B virus surface antigen levels - a guide to sustained response to pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B. HEPATOLOGY2009; doi:10.1002/hep.22760.
16. Heathcote EJ, Gane EJ, deMan RA, Sing C, Sievert W, Mauss S, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis [Abstract]. HEPATOLOGY2008; 48(Suppl):376A.
17. Bonino F, Marcellin P, Lau GKK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007;56:699-705.
18. Erhardt A, Ludwig AD, Brunetto M, van Boemmel F, Wolf E, Goebel T, et al. HBV genotypes are the strongest predictors of response to interferon-alfa treatment: Multivariate evaluation in 1229 hepatitis B patients [Abstract]. HEPATOLOGY2008;48(Suppl):700A.